There is a well-established and often underestimated connection between trauma and substance use disorders. For many individuals struggling with addiction, the roots of their substance use trace back not to a simple choice, but to a nervous system shaped by painful, unresolved experiences. Understanding this connection is no longer optional for those working in behavioural health. It is foundational.

On 16 April 2026, Dr Denis Antoine II, a board-certified psychiatrist and addiction medicine specialist at Johns Hopkins Bayview Medical Center, will lead a live training session exploring precisely this topic. The session, How Trauma Impacts SUD and Subsequent Treatment Efforts, is open to clinicians, counsellors, peer recovery specialists, social workers, and programme administrators, and offers up to 1.25 contact hours.

The Neurobiological Link Between Trauma and Substance Use Disorders

Trauma does not simply leave emotional scars. It physically alters the brain. When a person experiences chronic or acute trauma, particularly during childhood, the stress response systems become dysregulated. The hypothalamic-pituitary-adrenal (HPA) axis, which governs cortisol release, can become either hyperactive or blunted. The prefrontal cortex, responsible for decision-making and impulse control, loses some of its capacity to regulate the amygdala, the brain’s alarm centre.

This neurobiological disruption creates fertile ground for substance use. Research consistently shows that individuals with a history of adverse childhood experiences (ACEs) are significantly more likely to develop substance use disorders in adulthood. A landmark study published in the American Journal of Preventive Medicine found that individuals with four or more ACEs were five to twelve times more likely to use illicit substances compared to those with no adverse childhood experiences.

Substances, in this context, are not random choices. They become functional tools for managing an overwhelmed nervous system. Alcohol may dampen hypervigilance. Opioids may numb emotional pain. Stimulants may help individuals feel present and alive when dissociation takes hold. The substance use, however problematic, is often an attempt at self-regulation in the absence of healthier coping resources.

How Trauma Complicates Treatment Engagement

One of the most clinically significant consequences of trauma is its effect on how individuals engage with treatment. Trust, which is the very foundation of a therapeutic relationship, is often one of the first casualties of trauma. For someone whose traumatic experiences involved a caregiver, authority figure, or institution, entering a treatment programme can feel not like a refuge but a re-exposure to dynamics they have learned to fear.

This is why trauma and substance use disorders must be considered together, not sequentially. A clinician who addresses only the substance use without understanding its traumatic underpinnings may find a patient disengaging, missing appointments, or leaving treatment prematurely. These are not signs of poor motivation. They are often signs of an unaddressed trauma response.

Research supports this: individuals with co-occurring post-traumatic stress disorder (PTSD) and substance use disorders show significantly lower treatment retention rates compared to those without PTSD. They are also more likely to experience relapse, particularly when trauma symptoms are triggered during the recovery process.

Common Clinical Presentations to Recognise

Trauma does not always present in obvious ways within an addiction treatment setting. Clinicians who are familiar with the spectrum of trauma-related presentations are far better positioned to respond with empathy and precision.

Some of the most common presentations include persistent emotional dysregulation, difficulty tolerating distress, shame-based thinking, avoidance of therapeutic topics, dissociation during sessions, and a pattern of escalating substance use in response to environmental stressors. Individuals may appear guarded, hostile, or erratic, not because they are unwilling to engage, but because their nervous system has learned that vulnerability is dangerous.

Physical health complaints without clear medical explanation, sleep disturbances, and a history of multiple treatment episodes without sustained recovery are also common markers worth exploring with a trauma-informed lens.

Applying Trauma-Informed Principles in Addiction Care

Recognising trauma is only the first step. The real clinical challenge lies in embedding trauma-informed principles into the day-to-day fabric of addiction treatment. This means shifting from a model that asks “what is wrong with this person?” to one that asks “what happened to this person, and how has it shaped the way they are showing up today?”

Practically, this looks like creating physical and relational environments that feel predictably safe. It means being transparent about treatment expectations, offering choice wherever possible, and actively building collaborative rather than hierarchical therapeutic relationships. It also means training all staff, not only therapists, but intake workers, reception staff, and peer support specialists, to understand how trauma responses can manifest across every point of contact.

Screening for trauma early in the treatment process, and using validated tools such as the ACE questionnaire or the Trauma Screening Questionnaire, allows clinicians to tailor treatment plans that account for underlying trauma histories.

Integrated approaches that address trauma and substance use disorders simultaneously, such as Seeking Safety or Trauma-Focused Cognitive Behavioural Therapy adapted for addiction settings, have shown promising outcomes in improving both retention and recovery.

Why This Matters Now

The intersection of trauma-informed addiction treatment and public health has never been more urgent. In the United States alone, over 46 million people aged 12 or older met the criteria for a substance use disorder in 2021, according to the National Survey on Drug Use and Health. Simultaneously, population-level trauma exposure, including the lasting effects of the COVID-19 pandemic, community violence, and systemic inequality, continues to rise.

Clinicians and programme leaders who invest in deepening their understanding of trauma and substance use disorders are not simply improving individual outcomes. They are building systems that are more responsive, more humane, and ultimately more effective.

Dr Antoine’s upcoming session offers a structured opportunity to do exactly this. Whether you are a seasoned clinician seeking to refine your practice or a programme leader looking to embed trauma-informed principles across your service, this training provides a meaningful conceptual and practical foundation. (Source: WRD News)

When asked about their drinking habits, most people who consume alcohol above recommended levels have a strikingly similar response: “I’m not like those people.” This psychological phenomenon, known as othering amongst drinkers, has emerged as a significant obstacle in addressing alcohol harm across the UK and beyond.

Recent research examining 18 studies involving hundreds of participants reveals a troubling pattern. People drinking at risky levels consistently distance themselves from what they perceive as “real” problem drinkers. This happens even when their own consumption puts them at considerable health risk.

Understanding Othering Amongst Drinkers and Problem Recognition

Othering is the practice of constructing a problem “other,” someone fundamentally different from ourselves. In the context of alcohol, it means drawing sharp boundaries between one’s own “responsible” drinking and the problematic drinking of others.

This isn’t simply denial. Moreover, it’s a sophisticated set of strategies people use to maintain a positive self-image. Meanwhile, they continue potentially harmful behaviours. The research shows that othering amongst drinkers operates through several interconnected themes. Furthermore, each theme reinforces the belief that “I’m in control, not like them.” 

(Complete article WRD News)

A fentanyl vaccine will enter human trials in early 2026, offering a revolutionary approach to preventing drug use before it starts. Developed with support from the US Department of Defence and licensed by ARMR Sciences, the experimental treatment could become the first true biological deterrent against opioid use by making the drug completely ineffective.

The fentanyl vaccine trials will begin recruiting patients in the Netherlands, likely in January or February 2026. Animal studies showed the treatment completely eliminates fentanyl’s effects, removing any reason to use the drug in the first place.

Making Drug Use Pointless

Unlike existing approaches that manage addiction after it develops, this anti-fentanyl immunisation operates on a simple principle: if the drug doesn’t work, why would anyone bother taking it? “Our goal as a company is to eliminate the lethality of drugs on the market,” said Colin Gage, co-founder and chief executive of ARMR Sciences. “We want to do this by attacking the root cause not just of addiction, but obviously of overdose as well.”

The vaccine doesn’t just prevent death. It prevents the euphoria, the high, the entire point of using fentanyl. This represents a fundamental shift from managing consequences to eliminating motivation.

The Brutal Reality of Fentanyl

Fentanyl stands as a synthetic opioid approximately 50 times more potent than heroin. A dose of just 2 milligrams, equivalent to approximately 12 grains of salt, can prove deadly according to the US Drug Enforcement Administration.

Provisional data shows over 48,000 people died from opioid overdoses in the United States during 2024 alone. Thousands more became addicted, their lives derailed by a substance they often encountered unknowingly in contaminated street drugs.

The crisis demands a solution that prevents people from wanting to use these substances at all.

How the Fentanyl Vaccine Trials Will Work

The vaccine operates in the circulatory system, intercepting fentanyl before it reaches the brain. This represents the first treatment that doesn’t act on opioid receptors themselves but instead neutralises the drug entirely.

Because fentanyl molecules are too small to trigger natural immune responses, researchers attached them to other substances. The team, led by Colin Haile from the University of Houston and ARMR co-founder, selected an inactivated diphtheria toxin called CRM197, already used in existing vaccines.

To amplify the effect, researchers added dmLT, a compound obtained from modified bacteria. These components attach to a synthetic part of the fentanyl molecule.

Following vaccination, the immune system produces antibodies that bind to fentanyl, preventing it from crossing the blood-brain barrier. The drug gets eliminated from the body without ever producing euphoria, pain relief, or any rewarding sensation.

In rat studies, the anti-fentanyl immunisation blocked fentanyl from entering the brain completely. The rats showed no signs of euphoria, no behavioural changes, nothing. The drug simply didn’t work.

No High, No Point

This is the crucial deterrent effect. The vaccine doesn’t make fentanyl slightly less effective or reduce the high. It eliminates the high entirely.

“We’re targeting people who want to quit using,” Haile said. “The vaccine gives them the chance to understand they won’t get the desired effect anymore and that there’s no point in consuming the drug.”

For someone considering trying fentanyl, the vaccine removes any potential appeal. Why experiment with a deadly substance if you know it won’t produce any effect? The risk-reward calculation becomes absurd: all risk, zero reward.

For young people facing peer pressure or curiosity about drugs, the vaccine provides a biological shield. Even if they make a poor decision, the drug won’t work. They won’t experience the euphoria that drives continued use. The addiction cycle never begins because the initial reward never occurs.

Preventing the First Use

Traditional approaches focus on treating addiction after it develops. Education programmes warn about dangers but rely on people making good decisions under pressure. Treatment facilities help those already struggling but can’t reach people before they start using.

The anti-fentanyl immunisation changes this equation entirely. It prevents the drug from working at the biological level. Decision-making, peer pressure, moment of weakness—none of it matters if the drug produces no effect.

This represents true prevention. Not managing risk, not treating consequences, but stopping the problem before it starts.

The vaccine requires an initial dose followed by boosters at three and six weeks. Animal studies showed complete blockage of fentanyl effects six months after initial vaccination.

“The longest interval we’ve monitored animals was approximately six months, and we observed complete blocking of fentanyl effects,” Haile explained.

The 2026 Testing Protocol

The Phase I fentanyl vaccine trials scheduled for early 2026 will include 40 participants. The primary focus involves vaccine safety and potential adverse effects. Researchers will also monitor production of anti-fentanyl antibodies.

Success in this phase leads to Phase II studies testing vaccine efficacy. Some participants will receive safe doses of medical-grade fentanyl under strict supervision to verify the vaccine maintains its protective effect. The expectation: the drug will produce absolutely no response.

Both dmLT and CRM197 components have been tested in humans as parts of other vaccines. This provides safety reassurance as the treatment moves towards human trials.

Eliminating Temptation

In theory, someone could consume massive quantities of fentanyl to overwhelm the antibodies. However, researchers believe the absence of any euphoric effect will completely discourage this behaviour.

Think about it practically. If you take a drug and feel nothing—no high, no euphoria, no sensation whatsoever—why would you take more? The entire point of drug use disappears.

This isn’t willpower or self-control. It’s biology. The brain’s reward system never activates. The addiction pathway never forms. The behaviour has no reinforcement.

For parents worried about their children, for schools concerned about students, for communities devastated by drug deaths, this offers something unprecedented: a way to make the drug genuinely unappealing by making it genuinely useless.

Who Should Receive the Vaccine

The anti-fentanyl immunisation could serve young people before they ever encounter these substances. Vaccinating teenagers removes the possibility of fentanyl producing rewarding effects during vulnerable years when peer pressure peaks and decision-making remains immature.

People with family histories of substance use could receive protection before genetic vulnerability combines with environmental exposure. The vaccine breaks the intergenerational cycle by preventing the drug from working even if someone tries it.

Communities experiencing drug crises could offer widespread vaccination, creating a population where fentanyl simply doesn’t function. When enough people are vaccinated, the social dynamics around drug use shift. If your peers tell you the drug doesn’t work, experimentation loses its appeal.

“I lost two close childhood friends to fentanyl overdose,” Gage said, highlighting the personal stakes driving this research.

His friends likely didn’t set out to become addicted. They probably didn’t intend to die. They made decisions that spiralled into tragedy. The vaccine could prevent those spirals by preventing the initial effect that starts them.

Legitimate Medical Use

Fentanyl has legitimate medical applications, particularly as an analgesic in emergency situations. The vaccine’s specificity addresses this concern.

According to researchers, antibodies produced by the vaccine don’t bind to other opioids such as morphine, oxycodone, or methadone. Medical professionals retain options for managing severe pain whilst the vaccine protects against illicit fentanyl.

The treatment targets the specific threat whilst preserving medical tools. This specificity makes widespread vaccination practical.

A New Prevention Paradigm

Research shows both the general public and people directly affected by drug crises view an anti-fentanyl vaccine positively. The concept resonates: why not prevent drug use by making drugs ineffective?

This approach sidesteps debates about willpower, moral failing, or personal responsibility. It doesn’t matter why someone tries fentanyl if the drug produces no effect. The biological reality supersedes the psychological complexity.

For schools, this could become part of standard vaccination schedules. For communities, it could be offered alongside other public health interventions. For families, it provides peace of mind that even poor decisions won’t lead to addiction or death.

The fentanyl vaccine trials launching in 2026 represent a fundamentally different approach. Not managing addiction, not treating overdoses, not counselling users but preventing the entire problem by eliminating the drug’s appeal at the most basic level.

Changing the Calculation

Young people face constant messages about drugs. Media glamorises substance use. Peers experiment and report effects. Curiosity combines with adolescent risk-taking. Traditional prevention relies on education and fear, hoping young people make good decisions.

The vaccine changes this calculation entirely. It doesn’t ask teenagers to resist temptation through willpower. It removes the temptation by removing the reward.

Imagine telling young people: “You’re vaccinated. Even if you try fentanyl, nothing will happen. No high, no euphoria, nothing. It would be like taking a sugar pill, except dangerous and pointless.”

This message resonates differently than “just say no.” It’s not about being strong or making good choices. It’s about biological reality. The drug won’t work. Period.

What Happens Next

If approved following successful fentanyl vaccine trials, this would become an unprecedented tool in preventing drug use. Success would validate a completely new paradigm in substance abuse prevention.

Instead of focusing on consequences, society could offer protection before experimentation begins. Instead of treating addiction, we could prevent it by making the drug ineffective. Instead of hoping people resist temptation, we could eliminate the reward that creates temptation.

The vaccine doesn’t replace drug education. Young people still need to understand dangers. However, it provides a biological backstop. Even if education fails, even if someone makes a poor decision, the drug won’t work.

For families, this offers genuine hope. Not hope that loved ones will make good decisions under pressure. Hope that even bad decisions won’t lead to addiction because the drug simply won’t function.

For communities ravaged by opioid crises, it offers a path forward. Widespread vaccination could create a population where fentanyl loses its market. If the drug doesn’t produce effects, dealers can’t sell it. The economic model of drug trafficking collapses.

The Stakes in 2026

The anti-fentanyl immunisation entering trials in 2026 represents years of research finally reaching human testing. The approach is radical: don’t manage drug use, prevent it by making drugs useless.

With over 48,000 American deaths from opioid overdoses in 2024 alone, the urgency couldn’t be clearer. Traditional approaches haven’t solved the crisis. Education hasn’t stopped experimentation. Treatment hasn’t prevented deaths.

Perhaps the solution isn’t better education or better treatment. Perhaps it’s making the drug ineffective so there’s no point in using it at all.

The fentanyl vaccine trials beginning in 2026 will test whether this bold approach works in humans as it did in animals. If successful, it could mark a turning point. Not in how we treat addiction, but in how we prevent it from ever beginning.

(Source: WRD News)

Also See Naltrexone

Whilst stimulant-involved overdose deaths continue to climb across developed nations, a groundbreaking study has revealed that a relatively simple treatment approach could be saving thousands of lives if only it were widely available.

New research published in the American Journal of Psychiatry shows that contingency management treatment (a behavioural intervention that rewards people for meeting recovery milestones) reduced the risk of death by 41% amongst veterans with stimulant use disorder. That’s not a marginal improvement. That’s a life-saving intervention hiding in plain sight.

What Is Contingency Management Treatment?

Contingency management (CM) might sound complicated, but the concept is straightforward: reward positive behaviour to encourage more of it.

When someone with substance use disorder provides a negative drug test or participates in treatment activities, they receive tangible rewards like gift cards, vouchers, or social recognition. It’s based on a fundamental principle of human psychology: positive reinforcement works.

Previous research has consistently found contingency management to be effective in treating substance use disorders, with lower dropout rates and improved treatment outcomes. But this new study goes further. It proves that contingency management treatment doesn’t just help people stay in treatment. It keeps them alive. (Source: WRD News)

(Also see:

• Prizes for sobriety: As Washington meth use rises, this treatment is one of few that works
• Contingency Management for Abstinence as a Recovery Tool?
• Advancing Substance Use Disorder Treatments with Cognitive Remediation